Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
Market capitalisation
$2.03B
65,176,723 shares Covers every share class this company has on file.
Insiders on file
4
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$208.29M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
10.27%
insider-held value divided by market capitalisation
What Zenas BioPharma, Inc. reports
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Revenue
$10.00M
FY2025annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$377.74M
FY2025a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
167
Yahoo Finance
Where the employee count comes fromi
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Insiders at Zenas BioPharma, Inc.
Shares is what each person last reported holding here.i
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
Rows are grouped by the role each person reports.i
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
People who file insider reports against Zenas BioPharma, Inc..
POpen-market purchase Mar 31, 2026 position reported
Events from filings
Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.
Zenas BioPharma, Inc. (ZBIO) filed a Form 8-K under Item 5.02 (directors and officers) on Aug 13, 2026
Director or officer change filing
The company filed a current report that includes Item 5.02, the item used to report departures, elections or appointments of directors and certain officers, and related pay arrangements. We record only that this filing exists: we have not extracted who left, who joined or whose role changed. Open the filing to read it.
Form 8-K filed Aug 13, 2026, items 2.02, 5.02, 9.01. SEC filing ↗
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
3 insiders bought Zenas BioPharma, Inc. (ZBIO) shares worth $6,658,538 between Mar 30, 2026 and Apr 29, 2026
Cluster buying
3 different insiders made 7 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.
3 insiders bought Zenas BioPharma, Inc. (ZBIO) shares worth $6,658,538 between Mar 30, 2026 and Apr 29, 2026
Total of the rows above: $6,658,538, in the currency the filings report.
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Hongbo Lu bought 25,985 Zenas BioPharma, Inc. (ZBIO) shares for $584,663 on Feb 11, 2026
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Hongbo Lu bought 25,985 Zenas BioPharma, Inc. (ZBIO) shares for $584,663 on Feb 11, 2026
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Hongbo Lu bought 263,160 Zenas BioPharma, Inc. (ZBIO) shares for $5,000,040 on Oct 7, 2025
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Hongbo Lu bought 263,160 Zenas BioPharma, Inc. (ZBIO) shares for $5,000,040 on Oct 7, 2025
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Hongbo Lu bought 58,823 Zenas BioPharma, Inc. (ZBIO) shares for $999,991 on Sep 13, 2024
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Hongbo Lu bought 58,823 Zenas BioPharma, Inc. (ZBIO) shares for $999,991 on Sep 13, 2024
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Recent insider transactions
Of the 43 rows we hold,
33 are open-market
purchases (P) and
0 open-market
sales — the only codes we count as buying or selling.i
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
Insider transactions disclosed to the SEC for Zenas BioPharma, Inc., newest first, each with the filing behind it.
From SEC Form 4 filings. Every row links to the filing it
came from. How we calculate this.
What a Form 4 isi
The report an officer, director or large shareholder must file after trading their own company’s stock.
Corporate ownership links — 7 filers hold a position
Who owns Zenas BioPharma, Inc.
Each row is one filer naming this company.i
Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.
Do not add these figures together.
5 of the positions below were reported on filings shared by several filers at once.
Why the same shares appear twicei
On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.
Filers holding a position in Zenas BioPharma, Inc.
Funds, trusts and companies that disclose an ownership
position in Zenas BioPharma, Inc..
Think a number here is wrong?
Open the linked filing and compare —
how to report it.
Sources and technical notes
Every figure on this page comes from filings to the U.S. SEC via EDGAR.
Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
Zenas BioPharma, Inc.’s own filings and multiplied by our closing price.
Full method.
What that share count meansi
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure
is a share count from Zenas BioPharma, Inc.’s
own SEC filings multiplied by
the closing price we hold for the same stock.